A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virus–associated head and neck squamous cell cancer.

Authors

Charu Aggarwal

Hospital of the University of Pennsylvania, Medical Oncology, Philadelphia, PA

Charu Aggarwal , Balazs Halmos , Mercedes Porosnicu , Nabil F. Saba , Ammar Sukari , Sara Jo Grethlein , Ranee Mehra , Douglas Adkins , Mary J. Fidler , Rakesh Kumar , Jie Yang , Shaad Essa Abdullah , Missak Haigentz Jr.

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.

First Author: Tanguy Y. Seiwert

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.

First Author: Neil Howard Segal

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).

First Author: David A. Reardon

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

First Author: Lillian L. Siu